Literature DB >> 22740036

CTL recognition of HIV-1-infected cells via cross-recognition of multiple overlapping peptides from a single 11-mer Pol sequence.

Masao Hashimoto1, Tomohiro Akahoshi, Hayato Murakoshi, Naoki Ishizuka, Shinichi Oka, Masafumi Takiguchi.   

Abstract

It is known that overlapping HIV-1 peptides of different lengths can be presented by a given HLA class I molecule. However, the role of those peptides in CD8(+) T cells recognition of HIV-1-infected cells remains unclear. Here we investigated the recognition of overlapping 8-mer to 11-mer peptides of Pol 155-165 by HLA-B*54:01-restricted CD8(+) T cells. The analysis of ex vivo T cells using ELISPOT and tetramer binding assays showed that there were different patterns of CD8(+) T-cell responses to these peptides among chronically HIV-1-infected HLA-B*54:01(+) individuals, though the response to the 9-mer peptide was the strongest among them. CD8(+) T-cell clones with TCRs specific for the 9-mer, 10-mer, and/or 11-mer peptides effectively killed HIV-1-infected cells. Together, these results suggest that the 9-mer and 10-mer peptides could be predominantly presented by HLA-B*54:01, though it remains possible that the 11-mer peptide was also presented by this HLA allele. The present study demonstrates effective CD8(+) T-cell recognition of HIV-1-infected cells via presentation of multiple overlapping HIV-1 peptides and cross-recognition by the CD8(+) T cells.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740036     DOI: 10.1002/eji.201242483

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.

Authors:  Hayato Murakoshi; Nozomi Kuse; Tomohiro Akahoshi; Yu Zhang; Takayuki Chikata; Mohamed Ali Borghan; Hiroyuki Gatanaga; Shinichi Oka; Keiko Sakai; Masafumi Takiguchi
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.